| dbo:abstract
|
- Lefamulin ist ein antibiotisch wirksamer Arzneistoff aus der Gruppe der . In den USA ist es seit August 2019, in der EU seit Juli 2020 als Xenleta zur Behandlung ambulant erworbener Lungenentzündungen (Community-Acquired Bacterial Pneumonia, CABP) zugelassen. (de)
- Lefamulin, sold under the brand name Xenleta, is an antibiotic medication used it to treat adults with community-acquired bacterial pneumonia. It is taken by mouth or by injection into a vein. Relatively common side effects include diarrhea, nausea, pain at the site of injection, and liver inflammation. It is a pleuromutilin antibiotic that inhibits the large subunit of bacterial ribosomes. Lefamulin was approved for medical use in the United States in August 2019, and in the European Union in July 2020. (en)
- La léfamuline est un antibiotique de la famille des . (fr)
- Лефамулин — полусинтетический антибиотик класса плевромутилинов. Одобрен для применения: США(2019). (ru)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 10321 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalCa
| |
| dbp:legalEu
| |
| dbp:legalUs
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
|
- Intravenous, by mouth (en)
|
| dbp:s
| |
| dbp:smiles
|
- C[C@@H]1CC[C@@]23CCC[C@H]2[C@@]1C (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- KPVIXBKIJXZQJX-FCEONZPQSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Lefamulin ist ein antibiotisch wirksamer Arzneistoff aus der Gruppe der . In den USA ist es seit August 2019, in der EU seit Juli 2020 als Xenleta zur Behandlung ambulant erworbener Lungenentzündungen (Community-Acquired Bacterial Pneumonia, CABP) zugelassen. (de)
- Lefamulin, sold under the brand name Xenleta, is an antibiotic medication used it to treat adults with community-acquired bacterial pneumonia. It is taken by mouth or by injection into a vein. Relatively common side effects include diarrhea, nausea, pain at the site of injection, and liver inflammation. It is a pleuromutilin antibiotic that inhibits the large subunit of bacterial ribosomes. Lefamulin was approved for medical use in the United States in August 2019, and in the European Union in July 2020. (en)
- La léfamuline est un antibiotique de la famille des . (fr)
- Лефамулин — полусинтетический антибиотик класса плевромутилинов. Одобрен для применения: США(2019). (ru)
|
| rdfs:label
|
- Lefamulin (de)
- Léfamuline (fr)
- Lefamulin (en)
- Лефамулин (ru)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
